INSIDERFilingvia Quantisnow
Revance Therapeutics Inc. logo

Revance Therapeutics (RVNC) executive Foley sold 26,279 shares for $593K at $22.57 under a 10b5-1 plan

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Mark J Foley (executive at Revance Therapeutics Inc., RVNC) reported that they sold 26,279 shares for $593K at $22.57 on Aug 3, 2023. After these transactions the filing shows 840,375 shares held directly.

Reporting person
Foley Mark J
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Aug 3, 2023Open-market sale (S)Common Stock1, 2-26,279$22.57$593K840,375 direct

Holdings before and after

  • Common Stock: 866,654 to 840,375 direct

Other positions listed

  • Common Stock: 110,913 indirect, See footnote

Footnotes from the filing

  1. 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley.
  2. 2. The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.93 to $22.83. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. 3. These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

Transaction codes in this filing

Open-market sale:
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

FAQ

What did Foley report in this RVNC Form 4?

Mark J Foley (executive at Revance Therapeutics Inc., RVNC) reported that they sold 26,279 shares for $593K at $22.57 on Aug 3, 2023. After these transactions the filing shows 840,375 shares held directly.

How many RVNC shares does Foley hold after this filing?

The filing shows 840,375 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

Was this RVNC insider sale made under a 10b5-1 plan?

The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.

What does transaction code S mean on an SEC Form 4?

Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

Historical context for RVNC

Earlier insider filings at RVNC

Quantisnow market dataNASDAQ
Revance Therapeutics Inc. logo
RVNC
Revance Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2014
Get push alerts for RVNC

Follow RVNC and get a push notification the moment its next story breaks.

Full RVNC profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RVNC (Revance Therapeutics Inc.) and more on Quantisnow.